Last reviewed · How we verify
OLIMEL 7,6%E / PeriOLIMEL 2,5%E
Parenteral nutrition emulsion providing balanced amino acids, glucose, lipids, and electrolytes for intravenous metabolic support in patients unable to tolerate enteral feeding.
OLIMEL 7.6%E and PeriOLIMEL 2.5%E are parenteral nutrition (PN) emulsions developed by RWTH Aachen University, designed to provide comprehensive macronutrient and micronutrient support for patients unable to receive adequate enteral nutrition. These are lipid-based intravenous formulations containing amino acids, glucose, lipids, and electrolytes in a 3-in-1 or 2-in-1 admixture system, representing advances in PN formulation technology to improve metabolic tolerance and reduce complications associated with prolonged IV feeding. The products were developed as research-stage formulations and have been discontinued from commercial development, though they contributed to the scientific understanding of optimal PN composition. Clinical differentiation centered on improved lipid emulsion technology and balanced macronutrient ratios to reduce hyperglycemia and hepatic complications in critically ill and post-operative patients. These formulations did not achieve significant commercial scale and remain primarily of academic interest. The discontinuation reflects the competitive landscape of established PN manufacturers (Baxter, Fresenius Kabi, B. Braun) and regulatory barriers to bringing novel PN formulations to market.
At a glance
| Generic name | OLIMEL 7,6%E / PeriOLIMEL 2,5%E |
|---|---|
| Sponsor | RWTH Aachen University |
| Drug class | Parenteral nutrition emulsion |
| Target | Systemic metabolic support via balanced macronutrient delivery |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | discontinued |
Mechanism of action
OLIMEL and PeriOLIMEL are intravenous nutrition formulations designed to deliver complete macronutrient and micronutrient support directly into the bloodstream. The formulations contain a carefully balanced mixture of amino acids (providing nitrogen and protein synthesis substrates), glucose (primary energy source), lipid emulsions (essential fatty acids and additional calories), and electrolytes (sodium, potassium, calcium, magnesium, phosphate) in precise proportions. These 3-in-1 (OLIMEL) or 2-in-1 (PeriOLIMEL) admixtures are administered intravenously to patients with severe malnutrition, post-operative states, critical illness, or gastrointestinal dysfunction preventing adequate oral or enteral intake. The formulations aim to maintain nitrogen balance, prevent protein catabolism, support immune function, and reduce metabolic complications associated with prolonged parenteral nutrition such as hepatic steatosis, hyperglycemia, and refeeding syndrome.
Approved indications
Pipeline indications
- Parenteral nutrition support in critically ill patients — Research/Development
- Post-operative metabolic support — Research/Development